David Shook - 10 Feb 2026 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Reporting relationship: Chief Medical Officer
Issuer ticker: LYEL
Reported as of: 10 Feb 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 11 Feb 2026, 20:58:51 UTC
Prior SEC filing: 11 Jun 2025
Next SEC filing: 11 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Meltz, Attorney-in-Fact

Key filing fact

David Shook filed Form 4 for Lyell Immunopharma, Inc. (LYEL) on 11 Feb 2026.

Key facts

This page summarizes David Shook's Form 4 filing for Lyell Immunopharma, Inc. (LYEL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 11 Feb 2026, 20:58.

Change

Previous filing in this sequence was filed on 11 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001959742 Primary reporting owner

Shook David

Relationship: Chief Medical Officer
Address: C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SUITE 101, SOUTH SAN FRANCISCO
Signature: /s/ Mark Meltz, Attorney-in-Fact
Signature date: 11 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LYEL holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 21,900
Date: 10 Feb 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LYEL transaction Derivative

Option (right to buy)

Award

Transaction value: $0
Shares: +50,000
Change %
Price: $0.000000
Shares after: 50,000
Date: 10 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 50,000
Exercise price: $23.71
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Twelve and one-half percent (12.5%) of the total number of shares of Common Stock subject to the option will be vested and exercisable on the date that is six (6) months after February 9, 2026 (the "Vesting Commencement Date") and thereafter, an additional one fortyeighth (1/48th) of the shares will become vested and exercisable monthly on the same day as the Vesting Commencement Date (or, if there is no such corresponding day for a given month, on the last day of such month), until the option has become vested and exercisable with respect to one hundred percent (100%) of the shares, subject to the Reporting Person providing service to the Issuer through each applicable vesting date.